Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGQW52
|
|||
| Drug Name |
Lutetium Lu-177 vipivotide tetraxetan
|
|||
| Synonyms |
177Lu-labelled PSMA-617
Click to Show/Hide
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Approved | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | . | [2] |
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Metabolic pathways | ||||
| Vitamin digestion and absorption | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| Reactome | Amino acid synthesis and interconversion (transamination) | |||
| WikiPathways | One Carbon Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215833. | |||
| REF 2 | [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.